These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21834169)

  • 1. [Therapy of chronic hepatitis C: protease inhibitors significantly increase rate of healing].
    Stiefelhagen P; Einecke D
    MMW Fortschr Med; 2011 Jul; 153(29-31):14-5. PubMed ID: 21834169
    [No Abstract]   [Full Text] [Related]  

  • 2. [A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].
    Manns M
    MMW Fortschr Med; 2011 Jul; 153(29-31):17. PubMed ID: 21830729
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapy of chronic hepatitis C].
    Schaffstein S; Rampini SK; Müllhaupt B
    Praxis (Bern 1994); 2014 Apr; 103(8):423-36. PubMed ID: 24713377
    [No Abstract]   [Full Text] [Related]  

  • 5. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.
    Moucari R; Forestier N; Larrey D; Guyader D; Couzigou P; Benhamou Y; Voitot H; Vidaud M; Seiwert S; Bradford B; Zeuzem S; Marcellin P
    Gut; 2010 Dec; 59(12):1694-8. PubMed ID: 20861007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New triple therapy in chronic hepatitis C. Increased patient chances].
    Stiefelhagen P
    MMW Fortschr Med; 2011 Sep; 153(39):20. PubMed ID: 21991830
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of hepatitis C infection. A revolution should not hide another].
    Sogni P
    Presse Med; 2014 Apr; 43(4 Pt 1):339-40. PubMed ID: 24661837
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
    Salmerón J; Vinaixa C; Berenguer R; Pascasio JM; Sánchez Ruano JJ; Serra MÁ; Gila A; Diago M; Romero-Gómez M; Navarro JM; Testillano M; Fernández C; Espinosa D; Carmona I; Pons JA; Jorquera F; Rodriguez FJ; Pérez R; Montero JL; Granados R; Fernández M; Martín AB; Muñoz de Rueda P; Quiles R;
    World J Gastroenterol; 2015 Aug; 21(30):9163-74. PubMed ID: 26290644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    Inoue T; Hmwe SS; Shimada N; Kato K; Ide T; Torimura T; Kumada T; Toyoda H; Tsubota A; Takaguchi K; Wakita T; Tanaka Y
    PLoS One; 2017; 12(1):e0170667. PubMed ID: 28118381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infectious diseases. First specific drugs raise hopes for hepatitis C.
    Enserink M
    Science; 2011 Apr; 332(6026):159-60. PubMed ID: 21474720
    [No Abstract]   [Full Text] [Related]  

  • 11. An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments.
    Cobb B; Vilchez RA
    Hepatology; 2012 Mar; 55(3):979-80; author reply 980-1. PubMed ID: 22161994
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapy of hepatitis C: new inhibitors as hammers against HCV].
    Bublak R
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():10-1. PubMed ID: 23961643
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase 3 study results released for telaprevir and HCV.
    AIDS Patient Care STDS; 2010 Oct; 24(10):685-6. PubMed ID: 20945535
    [No Abstract]   [Full Text] [Related]  

  • 14. Telaprevir-induced DRESS.
    Kesar V; Kesar V; Khaitova V; Motamed D; Schiano T
    J Drugs Dermatol; 2014 Feb; 13(2):199-200. PubMed ID: 24509972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New times for the treatment of chronic hepatitis C].
    Gerstoft J; Fomsgaard A
    Ugeskr Laeger; 2012 Mar; 174(12):795. PubMed ID: 22433552
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
    de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H
    Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
    Silva MO; Treitel M; Graham DJ; Curry S; Frontera MJ; McMonagle P; Gupta S; Hughes E; Chase R; Lahser F; Barnard RJ; Howe AY; Howe JA
    J Hepatol; 2013 Jul; 59(1):31-7. PubMed ID: 23454058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis.
    Londoño MC; Perelló C; Cabezas J; Cañete N; Lens S; Mariño Z; Gambato M; Rodríguez R; Menéndez S; Carrión JA; Crespo J; Calleja JL; Forns X
    J Hepatol; 2015 Feb; 62(2):311-6. PubMed ID: 25281861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatitis C: therapeutic perspectives].
    Trépo C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B297-302. PubMed ID: 12180304
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.